CN110810521A - Composition for protecting eyesight and application thereof - Google Patents

Composition for protecting eyesight and application thereof Download PDF

Info

Publication number
CN110810521A
CN110810521A CN201911204456.9A CN201911204456A CN110810521A CN 110810521 A CN110810521 A CN 110810521A CN 201911204456 A CN201911204456 A CN 201911204456A CN 110810521 A CN110810521 A CN 110810521A
Authority
CN
China
Prior art keywords
milk powder
dha
lutein
zeaxanthin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911204456.9A
Other languages
Chinese (zh)
Inventor
周玉权
王晓彦
刘彪
周名桥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inner Mongolia Yili Industrial Group Co Ltd
Original Assignee
Inner Mongolia Yili Industrial Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inner Mongolia Yili Industrial Group Co Ltd filed Critical Inner Mongolia Yili Industrial Group Co Ltd
Priority to CN201911204456.9A priority Critical patent/CN110810521A/en
Publication of CN110810521A publication Critical patent/CN110810521A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

The application relates to a composition for protecting eyesight and application thereof. The composition comprises DHA, zeaxanthin and lutein as active ingredients, wherein the pure content of each active ingredient is as follows: 10-300 parts of DHA, 1 part of zeaxanthin and 0.15-3.5 parts of lutein. The composition can significantly improve vision and can be used for preventing or alleviating the degree of vision deterioration, and has the effect of protecting vision.

Description

Composition for protecting eyesight and application thereof
Technical Field
The invention relates to the field of food, in particular to a composition for protecting eyesight and application thereof.
Background
The lutein and zeaxanthin ((3R,3' R) -dihydroxy- β -carotene) are the only nutrients present in the fundus of the eye and are specifically accumulated in the eye after being absorbed by the human body to help filter harmful blue light, and the zeaxanthin and the lutein are isomers of each other, and are different in that the position of the double bond of one of the ionone rings is different, and they are the only carotenoid highly concentrated in the macula part of the retina in the eye and are the main components of the macula pigment.
The inventor finds that the zeaxanthin and the lutein are matched with the DHA in the research process to obviously improve the vision and prevent or relieve the vision deterioration degree, and the zeaxanthin and the lutein have the effect of protecting the vision. In addition, in the using process, as the three components are easily oxidized and damaged, the composition obtained by processing in a special embedding mode can keep stable in property for a long time and can exert the optimal effect.
Disclosure of Invention
In one aspect, the present application provides a composition comprising DHA, zeaxanthin and lutein as active ingredients, wherein the active ingredients are as follows on a pure basis:
10-300 parts of DHA;
1 part by weight of zeaxanthin;
0.15-3.5 parts by weight of lutein.
In some embodiments, the compositions comprise the following active ingredients, in pure form:
200 parts of DHA;
1 part by weight of zeaxanthin;
2 parts of lutein.
In some embodiments, the DHA, zeaxanthin, and lutein are used as a powder in microencapsulated form.
For example, the DHA is a DHA algal oil meal or DHA fish oil meal in a microencapsulated form, wherein the DHA content is 5-15%. In some preferred embodiments, the DHA algal oil meal or DHA fish oil meal has a DHA content of 7-10%. In some preferred embodiments, the DHA algal oil meal or DHA fish oil meal has a DHA content of 7%.
For example, the zeaxanthin is microcapsule powder embedded by modified starch or maltodextrin with or without vitamin E, vitamin C or vitamin A, and the content of the microcapsule powder is 0.05-10%. In some embodiments, the zeaxanthin is a microcapsule powder with a zeaxanthin content of 0.5-5% embedded by starch sodium octenyl succinate, vitamin E, and the like. In some preferred embodiments, the zeaxanthin content of the zeaxanthin microcapsules is 5%.
For example, the lutein is microcapsule powder with the content of 0.05-10% embedded by modified starch or maltodextrin and with or without vitamin E, vitamin C or vitamin A. In some embodiments, the lutein is microcapsule powder with lutein content of 0.1-5% embedded by starch sodium octenyl succinate, vitamin E and other materials. In some preferred embodiments, the lutein content in the lutein microcapsule is 0.5%.
In some embodiments, the composition further comprises one or more of the following: vitamin A, taurine, zinc, blueberry or blueberry extract, cranberry or cranberry extract, cowberry or cowberry extract, anthocyanin, cassia seed or cassia seed extract, and lycium ruthenicum or lycium ruthenicum extract.
In some embodiments, the composition is a reconstituted milk powder.
In some embodiments, the composition comprises the following components in weight percent: 90-99.5% of modified milk powder base powder, 0.01-0.08% of DHA (calculated by pure product), 0.0008-0.01% of zeaxanthin (calculated by pure product) and 0.0016-0.005% of lutein (calculated by pure product); optionally, the composition further comprises one or more of vitamin a, taurine, zinc, blueberry extract, cranberry extract, cowberry extract and anthocyanins.
The modified milk powder base powder disclosed by the invention meets the regulation of GB14880 on modified milk powder, namely, raw cow (sheep) milk or a processed product thereof is used as a main raw material, other raw materials are added, and a food additive and a nutrition enhancer are added or not added, so that a powdered product with the milk solid content of not less than 70% is prepared. Raw materials used by the method include but are not limited to raw cow (sheep) milk, whole milk powder (including instant type and non-instant type), skimmed milk powder (including instant type and non-instant type), whey powder, whey protein powder, white granulated sugar, lactose, solid corn syrup, maltodextrin, vegetable oil, milk mineral salt, calcium carbonate, phospholipid, anhydrous cream, compound vitamins, compound minerals and the like. The base powder can be prepared by using the raw materials according with the regulation of the prepared milk powder at any ratio.
In some preferred embodiments, the modified milk powder comprises the following components:
40-60% of full cream milk powder, 20-35% of skim milk powder, 8-15% of white granulated sugar, 5-8% of lactose, 0.1-1% of milk mineral salt, 0.05-0.5% of phospholipid, 0.01-0.075% of DHA (docosahexaenoic acid), 0.0008-0.01 per mill of zeaxanthin, 0.00162-0.01 per mill of lutein and the balance of maltodextrin
In some preferred embodiments, the composition comprises the following ingredients:
56% of full cream milk powder, 22.5% of skim milk powder, 12.5% of white granulated sugar, 5% of lactose, 0.6% of milk mineral salt, 0.1% of phospholipid, 0.0245% of DHA, 0.0013% of zeaxanthin, 0.0025% of lutein and the balance of maltodextrin.
In another aspect, the present application provides the use of the aforementioned composition or modified milk powder in the preparation of a medicament or health product for protecting vision (preventing or slowing down vision loss).
Advantageous effects of the invention
The present application provides a composition containing DHA, zeaxanthin and lutein, which can significantly improve vision and can be used to prevent or alleviate the degree of vision deterioration, having a vision-protecting effect.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but those skilled in the art will appreciate that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
DHA (type: DHA fish oil powder, lot # 20180523, origin: Denmark; type: DHA algal oil powder, lot # 20180726, origin: Denmark) in the following examples was supplied by BASF (China) Co., Ltd., zeaxanthin (type: OPTISHARP)TMNatural 5% CWS/S-TG, batch number: 18045007, origin: spanish) and lutein (type: fortitech Premixes 0.5% lutein, lot number: VR18121256, origin: shanghai) was provided by imperial vitamin (shanghai) ltd.
Example 1:
this example provides a composition for protecting vision. The composition comprises the following active ingredients in pure product: 10 parts of DHA, 1 part of zeaxanthin and 0.15 part of lutein. Wherein the DHA is microcapsule-embedded algae oil powder with DHA content of 7%; the zeaxanthin is microcapsule embedded by starch sodium octenyl succinate, vitamin E, etc. and has zeaxanthin content of 5%. The lutein is microcapsule with lutein content of 0.5% embedded by starch sodium octenyl succinate, vitamin E, etc. The resulting mixture was dry blended for 5min by a V-shaped dry blender to give a well-mixed composition.
Example 2:
this example provides a composition for protecting vision. The composition comprises the following active ingredients in pure product: 10 parts of DHA, 1 part of zeaxanthin and 3.5 parts of lutein. Wherein the DHA is microcapsule-embedded algae oil powder with DHA content of 7%; the zeaxanthin is microcapsule embedded by starch sodium octenyl succinate, vitamin E, etc. and has zeaxanthin content of 5%. The lutein is microcapsule with lutein content of 0.5% embedded by starch sodium octenyl succinate, vitamin E, etc. The resulting mixture was dry blended for 5min by a V-shaped dry blender to give a well-mixed composition.
Example 3:
this example provides a composition for protecting vision. The composition comprises the following active ingredients in pure product: 300 parts of DHA, 1 part of zeaxanthin and 0.15 part of lutein. Wherein the DHA is microcapsule-embedded algae oil powder with DHA content of 7%; the zeaxanthin is microcapsule embedded by starch sodium octenyl succinate, vitamin E, etc. and has zeaxanthin content of 5%. The lutein is microcapsule with lutein content of 0.5% embedded by starch sodium octenyl succinate, vitamin E, etc. The resulting mixture was dry blended for 5min by a V-shaped dry blender to give a well-mixed composition.
Example 4:
this example provides a composition for protecting vision. The composition comprises the following active ingredients in pure product: 300 parts of DHA, 1 part of zeaxanthin and 3.5 parts of lutein. Wherein the DHA is microcapsule-embedded algae oil powder with DHA content of 7%; the zeaxanthin is microcapsule embedded by starch sodium octenyl succinate, vitamin E, etc. and has zeaxanthin content of 5%. The lutein is microcapsule with lutein content of 0.5% embedded by starch sodium octenyl succinate, vitamin E, etc. The resulting mixture was dry blended for 5min by a V-shaped dry blender to give a well-mixed composition.
Example 5:
this example provides a composition for protecting vision. The composition comprises the following active ingredients in pure product: 200 parts of DHA, 1 part of zeaxanthin and 2 parts of lutein. Wherein the DHA is microcapsule-embedded algae oil powder with DHA content of 7%; the zeaxanthin is microcapsule embedded by starch sodium octenyl succinate, vitamin E, etc. and has zeaxanthin content of 5%. The lutein is microcapsule with lutein content of 0.5% embedded by starch sodium octenyl succinate, vitamin E, etc. The resulting mixture was dry blended for 5min by a V-shaped dry blender to give a well-mixed composition.
Example 6:
this embodiment provides a reconstituted milk powder to which a composition is added, the reconstituted milk powder comprising: 56% of whole milk powder, 22.5% of skimmed milk powder, 12.5% of white granulated sugar, 5% of lactose, 0.6% of milk mineral salt, 0.1% of phospholipid, 0.35% of DHA fish oil powder (with the purity of 7%), 0.0025% of zeaxanthin (with the purity of 5%), 0.05% of lutein (with the purity of 0.5%), and the balance of maltodextrin.
1) Mixing materials: adding a certain amount of warm water of 50 ℃ into a wet mixing tank, respectively sucking whole milk powder, skimmed milk powder, white granulated sugar, lactose, milk mineral salt and maltodextrin into the wet mixing tank, stirring and mixing, wherein the final material liquid concentration is 21%, and the mixing temperature is 50 ℃.
2) The phospholipids were sucked into the wet mix tank through a small hopper.
3) Homogenizing: the homogenization pressure (one/two stage) was (110/40). + -. 2bar, the homogenization temperature was 60 ℃.
4) Pasteurizing: the sterilization temperature is 91 ℃, and the sterilization time is 20 s.
5) Concentration: the concentration temperature is 55 ℃, and the concentration of the finally obtained feed liquid is 48%.
6) Spray drying: the main air inlet temperature is 190 ℃, the air exhaust temperature is 85 ℃, and the powder outlet temperature is 30 ℃. Obtaining base powder.
7) Premixing: mixing 20kg of base powder with DHA powder, zeaxanthin powder and lutein powder for 20min to obtain premix.
8) Dry mixing: and dry-mixing the premix and the rest base powder for 4min to obtain the uniformly dried modulated milk powder.
Comparative example 1:
the present comparative example provides a reconstituted milk powder with an added composition, the reconstituted milk powder comprising: 56% of whole milk powder, 22.5% of skimmed milk powder, 12.5% of white granulated sugar, 5% of lactose, 0.6% of milk mineral salt, 0.1% of phospholipid and the balance of maltodextrin.
1) Mixing materials: adding a certain amount of warm water of 50 ℃ into a wet mixing tank, respectively sucking whole milk powder, skimmed milk powder, white granulated sugar, lactose, milk mineral salt and maltodextrin into the wet mixing tank, stirring and mixing, wherein the final material liquid concentration is 21%, and the mixing temperature is 50 ℃.
2) The phospholipids were sucked into the wet mix tank through a small hopper.
3) Homogenizing: the homogenization pressure (one/two stage) was (110/40). + -. 2bar, the homogenization temperature was 60 ℃.
4) Pasteurizing: the sterilization temperature is 91 ℃, and the sterilization time is 20 s.
5) Concentration: the concentration temperature is 55 ℃, and the concentration of the finally obtained feed liquid is 48%.
6) Spray drying: the main air inlet temperature is 190 ℃, the air exhaust temperature is 85 ℃, and the powder outlet temperature is 30 ℃. And obtaining a finished product.
Comparative example 2:
the present comparative example provides a reconstituted milk powder with an added composition, the reconstituted milk powder comprising: 56% of whole milk powder, 22.5% of skimmed milk powder, 12.5% of white granulated sugar, 5% of lactose, 0.6% of milk mineral salt, 0.1% of phospholipid, 0.0025% of zeaxanthin (with the purity of 5%), 0.05% of lutein (with the purity of 0.5%) and the balance of maltodextrin.
1) Mixing materials: adding a certain amount of warm water of 50 ℃ into a wet mixing tank, respectively sucking whole milk powder, skimmed milk powder, white granulated sugar, lactose, milk mineral salt and maltodextrin into the wet mixing tank, stirring and mixing, wherein the final material liquid concentration is 21%, and the mixing temperature is 50 ℃.
2) The phospholipids were sucked into the wet mix tank through a small hopper.
3) Homogenizing: the homogenization pressure (one/two stage) was (110/40). + -. 2bar, the homogenization temperature was 60 ℃.
4) Pasteurizing: the sterilization temperature is 91 ℃, and the sterilization time is 20 s.
5) Concentration: the concentration temperature is 55 ℃, and the concentration of the finally obtained feed liquid is 48%.
6) Spray drying: the main air inlet temperature is 190 ℃, the air exhaust temperature is 85 ℃, and the powder outlet temperature is 30 ℃. Obtaining base powder.
7) Premixing: mixing 20kg of base powder with zeaxanthin powder and lutein powder for 20min to obtain premix.
8) Dry mixing: and dry-mixing the premix and the rest base powder for 4min to obtain the uniformly dried modulated milk powder.
Comparative example 3:
the present comparative example provides a reconstituted milk powder with an added composition, the reconstituted milk powder comprising: 56% of whole milk powder, 22.5% of skimmed milk powder, 12.5% of white granulated sugar, 5% of lactose, 0.6% of milk mineral salt, 0.1% of phospholipid, 0.35% of DHA fish oil powder (with the purity of 7%), 0.05% of lutein (with the purity of 0.5%), and the balance of maltodextrin.
1) Mixing materials: adding a certain amount of warm water of 50 ℃ into a wet mixing tank, respectively sucking whole milk powder, skimmed milk powder, white granulated sugar, lactose, milk mineral salt and maltodextrin into the wet mixing tank, stirring and mixing, wherein the final material liquid concentration is 21%, and the mixing temperature is 50 ℃.
2) The phospholipids were sucked into the wet mix tank through a small hopper.
3) Homogenizing: the homogenization pressure (one/two stage) was (110/40). + -. 2bar, the homogenization temperature was 60 ℃.
4) Pasteurizing: the sterilization temperature is 91 ℃, and the sterilization time is 20 s.
5) Concentration: the concentration temperature is 55 ℃, and the concentration of the finally obtained feed liquid is 48%.
6) Spray drying: the main air inlet temperature is 190 ℃, the air exhaust temperature is 85 ℃, and the powder outlet temperature is 30 ℃. Obtaining base powder.
7) Premixing: mixing 20kg of base powder with DHA powder and lutein powder for 20min to obtain premix.
8) Dry mixing: and dry-mixing the premix and the rest base powder for 4min to obtain the uniformly dried modulated milk powder.
Comparative example 4:
the present comparative example provides a reconstituted milk powder with an added composition, the reconstituted milk powder comprising: 56% of whole milk powder, 22.5% of skimmed milk powder, 12.5% of white granulated sugar, 5% of lactose, 0.6% of milk mineral salt, 0.1% of phospholipid, 0.35% of DHA fish oil powder (with the purity of 7%), 0.0025% of zeaxanthin (with the purity of 5%), and the balance of maltodextrin.
1) Mixing materials: adding a certain amount of warm water of 50 ℃ into a wet mixing tank, respectively sucking whole milk powder, skimmed milk powder, white granulated sugar, lactose, milk mineral salt and maltodextrin into the wet mixing tank, stirring and mixing, wherein the final material liquid concentration is 21%, and the mixing temperature is 50 ℃.
2) The phospholipids were sucked into the wet mix tank through a small hopper.
3) Homogenizing: the homogenization pressure (one/two stage) was (110/40). + -. 2bar, the homogenization temperature was 60 ℃.
4) Pasteurizing: the sterilization temperature is 91 ℃, and the sterilization time is 20 s.
5) Concentration: the concentration temperature is 55 ℃, and the concentration of the finally obtained feed liquid is 48%.
6) Spray drying: the main air inlet temperature is 190 ℃, the air exhaust temperature is 85 ℃, and the powder outlet temperature is 30 ℃. Obtaining base powder.
7) Premixing: mixing 20kg of base powder with DHA powder and zeaxanthin powder for 20min to obtain premix.
8) Dry mixing: and dry-mixing the premix and the rest base powder for 4min to obtain the uniformly dried modulated milk powder.
Effect test
The following efficacy verification tests describe the effect of the vision-protecting compositions provided by the present invention on vision protection.
Effect verification test 500 cases of healthy population of 6-15 years old were selected and randomly divided into 5 groups, i.e., control group, test group 1, test group 2, test group 3, and test group 4, each group including 100 cases. Their visual scores were tested and recorded using a standard logarithmic visual chart prior to the trial (5 points system). Then, different prepared milk powders were distributed to the respective components, that is, the control group consumed the prepared milk powder prepared by adding the composition of comparative example 1, the test group 1 consumed the prepared milk powder prepared by adding the composition of example 6, the test group 2 consumed the prepared milk powder prepared by adding the composition of comparative example 2, the test group 3 consumed the prepared milk powder prepared by adding the composition of comparative example 3, and the test group 4 consumed the prepared milk powder prepared by adding the composition of comparative example 4. Each person is required to drink one milk powder (25g) each time in the morning and at night every day and distribute the milk powder once a month. And testing the vision again after 12 months, correspondingly recording the vision scores of the users, and calculating the naked eye vision decline value. And finally counting the percentage of the corresponding people to the total number of people tested in each group according to the degree of naked eye vision decline as a judgment index. The results are shown in the following table.
Result analysis table for effect verification test
Figure BDA0002296631410000091
The result shows that the composition for protecting vision provided by the invention can be applied to the modified milk powder to obviously improve vision and prevent or relieve the degree of vision deterioration. If any one or more of the above-mentioned DHA, zeaxanthin, and lutein is absent from the formulation, the effects of improving vision and preventing or alleviating vision loss are significantly reduced. Therefore, the matching of the components in the modified milk powder which is helpful for protecting eyesight is very important, so that the components have certain synergistic effect while exerting the effects.
Although specific embodiments of the invention have been described in detail, it will be appreciated by those skilled in the art that, based upon the overall teachings of the disclosure, various modifications and alternatives to those details could be developed and still be encompassed by the present invention. The full scope of the invention is given by the appended claims and any equivalents thereof.

Claims (9)

1. A composition comprises DHA, zeaxanthin and lutein as active ingredients, wherein the content of each active ingredient in a pure product is as follows:
10-300 parts of DHA;
1 part by weight of zeaxanthin;
0.15-3.5 parts by weight of lutein;
preferably, the first and second electrodes are formed of a metal,
200 parts of DHA;
1 part by weight of zeaxanthin;
2 parts of lutein.
2. The composition according to claim 1, wherein the DHA is in microencapsulated form as DHA algal oil meal or DHA fish oil meal, the DHA content in the microcapsules being 5-15%, preferably 7-10%, more preferably 7%.
3. The composition of claim 1 or 2, wherein the zeaxanthin is in a microencapsulated form, the zeaxanthin content of the microcapsules being from 0.05 to 10%, preferably from 0.5 to 5%, more preferably 5%.
4. A composition according to any one of claims 1-3, wherein the lutein is in a microencapsulated form, the lutein content in the microcapsule being 0.05-10%, preferably 0.1-5%, more preferably 0.5%.
5. The composition of any one of claims 1-4, further comprising one or more of the following: vitamin A, taurine, zinc, blueberry or blueberry extract, cranberry or cranberry extract, cowberry or cowberry extract, anthocyanin, cassia seed or cassia seed extract, and lycium ruthenicum or lycium ruthenicum extract.
6. The composition of any one of claims 1 to 5, which is a reconstituted milk powder.
7. A reconstituted milk powder or a composition according to claim 6, comprising the following components in weight percent: 90-99.5% of modified milk powder base powder, 0.01-0.08% of DHA (calculated by pure product), 0.0008-0.01% of zeaxanthin (calculated by pure product) and 0.0016-0.005% of lutein (calculated by pure product); optionally, the composition further comprises one or more of vitamin a, taurine, zinc, blueberry extract, cranberry extract, cowberry extract and anthocyanins; preferably, the modified milk powder base powder is selected from one or more of the following: raw cow (sheep) milk, whole milk powder, skimmed milk powder, whey protein powder, white granulated sugar, lactose, solid corn syrup, maltodextrin, vegetable oil, milk mineral salt, calcium carbonate, phospholipid, anhydrous cream, compound vitamins and compound minerals.
8. The reconstituted milk powder or composition of claim 7, comprising the following ingredients:
40-60% of full cream milk powder, 20-35% of skim milk powder, 8-15% of white granulated sugar, 5-8% of lactose, 0.1-1% of milk mineral salt, 0.05-0.5% of phospholipid, 0.01-0.08% of DHA, 0.0008-0.01% of zeaxanthin, 0.0016-0.005% of lutein and the balance of maltodextrin;
preferably, the modified milk powder or the composition contains the following components:
56% of full cream milk powder, 22.5% of skim milk powder, 12.5% of white granulated sugar, 5% of lactose, 0.6% of milk mineral salt, 0.1% of phospholipid, 0.0245% of DHA, 0.0013% of zeaxanthin, 0.0025% of lutein and the balance of maltodextrin.
9. Use of a composition according to any one of claims 1 to 8 or a reconstituted milk powder according to claim 7 or 8 in the manufacture of a medicament for the protection of vision (prevention or slowing of vision loss).
CN201911204456.9A 2019-11-29 2019-11-29 Composition for protecting eyesight and application thereof Pending CN110810521A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911204456.9A CN110810521A (en) 2019-11-29 2019-11-29 Composition for protecting eyesight and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911204456.9A CN110810521A (en) 2019-11-29 2019-11-29 Composition for protecting eyesight and application thereof

Publications (1)

Publication Number Publication Date
CN110810521A true CN110810521A (en) 2020-02-21

Family

ID=69543347

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911204456.9A Pending CN110810521A (en) 2019-11-29 2019-11-29 Composition for protecting eyesight and application thereof

Country Status (1)

Country Link
CN (1) CN110810521A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112167632A (en) * 2020-09-27 2021-01-05 深圳乾宏生物科技有限公司 Preparation method of DHA (docosahexaenoic acid) children brain nutrition tablets

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103859062A (en) * 2012-12-18 2014-06-18 山东西王食品有限公司 Edible corn oil having quintuple eyesight protection functions
CN106692187A (en) * 2015-11-16 2017-05-24 浙江医药股份有限公司新昌制药厂 Composition for improving visuognosis persistence and protecting eye health
CN108041609A (en) * 2017-12-04 2018-05-18 广州正广生物科技有限公司 One kind, which has, alleviates visual fatigue, pre- myopic-preventing food compositions and preparation method thereof
CN108077438A (en) * 2017-12-29 2018-05-29 澳优乳业（中国）有限公司 A kind of eyeshield modulation milk powder and preparation method thereof
CN108354180A (en) * 2018-05-24 2018-08-03 江西人之初营养科技股份有限公司 A kind of composition and its application for helping to alleviate blue ray radiation injury
CN109645201A (en) * 2019-02-22 2019-04-19 四川益康天成生物科技开发有限公司 Composition containing lutein and lutein ester, lutein pressed candy and preparation method and application
CN109938146A (en) * 2019-03-22 2019-06-28 西安梵帝罗光学科技有限公司 A kind of blueberry lutein ester pressed candy and preparation method
CN110178901A (en) * 2019-05-28 2019-08-30 石家庄君乐宝乳业有限公司 Containing the high eyeshield solid-state modulation milk powder and preparation method thereof of breast amount
CN110226751A (en) * 2019-07-10 2019-09-13 完美（广东）日用品有限公司 A kind of composition with eye protection effect

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103859062A (en) * 2012-12-18 2014-06-18 山东西王食品有限公司 Edible corn oil having quintuple eyesight protection functions
CN106692187A (en) * 2015-11-16 2017-05-24 浙江医药股份有限公司新昌制药厂 Composition for improving visuognosis persistence and protecting eye health
CN108041609A (en) * 2017-12-04 2018-05-18 广州正广生物科技有限公司 One kind, which has, alleviates visual fatigue, pre- myopic-preventing food compositions and preparation method thereof
CN108077438A (en) * 2017-12-29 2018-05-29 澳优乳业（中国）有限公司 A kind of eyeshield modulation milk powder and preparation method thereof
CN108354180A (en) * 2018-05-24 2018-08-03 江西人之初营养科技股份有限公司 A kind of composition and its application for helping to alleviate blue ray radiation injury
CN109645201A (en) * 2019-02-22 2019-04-19 四川益康天成生物科技开发有限公司 Composition containing lutein and lutein ester, lutein pressed candy and preparation method and application
CN109938146A (en) * 2019-03-22 2019-06-28 西安梵帝罗光学科技有限公司 A kind of blueberry lutein ester pressed candy and preparation method
CN110178901A (en) * 2019-05-28 2019-08-30 石家庄君乐宝乳业有限公司 Containing the high eyeshield solid-state modulation milk powder and preparation method thereof of breast amount
CN110226751A (en) * 2019-07-10 2019-09-13 完美（广东）日用品有限公司 A kind of composition with eye protection effect

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
汪之顼: "叶黄素和玉米黄质对视觉发育和健康的影响", 《国外医学(卫生学分册)》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112167632A (en) * 2020-09-27 2021-01-05 深圳乾宏生物科技有限公司 Preparation method of DHA (docosahexaenoic acid) children brain nutrition tablets

Similar Documents

Publication Publication Date Title
Botsoglou et al. The effect of feeding rosemary, oregano, saffron and α-tocopheryl acetate on hen performance and oxidative stability of eggs
CN100374044C (en) Primary composition containing lipophilic bioactive compound
EP2138055B2 (en) Formula food to be beneficial for visuognosis persistence and use thereof
Florou-Paneri et al. Oregano herb versus oregano essential oil as feed supplements to increase the oxidative stability of turkey meat
DE202009018158U1 (en) Chia seed composition
CN109315491A (en) A kind of baby formula milk powder and preparation method thereof promoting visual acuity
US20200390793A1 (en) Compositions and methods using oleuropein or curcumin for muscle quality and/or muscle mass
US20140113031A1 (en) Nutritional Shake
Esmaeili et al. Encapsulating vitamin D: A feasible and promising approach to combat its deficiency
KR100647067B1 (en) Feed composition comprising Rubus coreanus for poultry and the egg produced by feeding the same
CN110810521A (en) Composition for protecting eyesight and application thereof
KR20060115369A (en) Calcium dietary supplement
EP1049384B1 (en) Method for producing an easily digestible protein concentrate, a protein-rich food item and its use
ES2247829T3 (en) PROCEDURE FOR THE MANUFACTURE OF A BIOLOGICAL SUBSTANCE AS WELL AS A BIOLOGICAL SUBSTANCE OF THIS TYPE AND ITS USE.
RU2372797C1 (en) Mayonnaise and protein sauce preparation method
US9161960B2 (en) Horse feed dietary supplement composition derived from chia seed composition
US20230096487A1 (en) Undenatured Type II Collagen in Food and Beverage Applications and Uses Thereof
RU2363268C1 (en) Dietary supplement
CN109793123A (en) Laying hen multivitamin nutrient selenium-rich zoology feed
RU2192763C2 (en) Food emulsion and method of its preparation
RU2376781C1 (en) Revitalising food emulsion "krozam" and its production method
RU2794759C2 (en) Method for feeding pets and horses and therapeutic and preventive feed additive for its implementation
KR20140072893A (en) Sensation-improving agent
RU2660263C1 (en) Caramel with filling of functional purpose with hypolipidemic properties to improve memory processes
RU2385660C2 (en) Vegetable concentrate for functional drink "kazan-bionan-2"

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200221